Premium
Clinical Trials of Immunoadsorbent in Systemic Lupus Erythematosus Therapy
Author(s) -
Gao ChunLi,
Li BaoAn,
Chen ChangZhi,
Yu YaoTing,
Yuan Ping,
Song JiChang
Publication year - 1995
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1995.tb02360.x
Subject(s) - medicine , ascites , edema , antibody , dna , joint pain , gastroenterology , lupus erythematosus , immunology , chemistry , biochemistry
Five patients with systemic lupus erythematosus (SLE) were perfused through an extracorporeal shunt filled with DNA‐immunoadsorbent (DNA immobilized on carbonized resin beads). High concentrations of anti‐DNA antibodies (36.4–67.0%) (binding percentage with 125 I‐DNA) in the serum of SLE patients were reduced to 13.8–53.0%, respectively. The highest removal percentage was 62.1%. Although the decline levels varied, the symptoms of patients, i.e., long‐term severe joint pain, severe edema, hydropericardium, and ascites were all relieved considerably. The immunoadsorbent showed satisfactory blood compatibility.